
Dec 19 (Reuters) - Spero Therapeutics Inc SPRO.O:
SPERO ANNOUNCES NDA RESUBMISSION OF TEBIPENEM HBR BY GSK TO THE FDA FOR THE TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS, INCLUDING PYELONEPHRITIS
SPERO THERAPEUTICS INC - NDA SUBMISSION TRIGGERS $25 MILLION MILESTONE PAYMENT TO SPERO